Online Program

329114
Physician attitudes on the Center for Medicare and Medicaid Service's bundled payment initiative


Tuesday, November 3, 2015 : 5:00 p.m. - 5:15 p.m.

Rebecca Alleyne, M.D., M.H.A., F.A.C.S, Rebecca S. Alleyne M.D., Studio City, CA
Medicare Payment Bundling is one proposed reform of the Affordable Care Act.  The Center for Medicare and Medicaid Services proposed four models of payment bundling to be launched as pilot programs.  This study is a physician opinion survey on the affect of proposed models on clinical decision making. The survey was distributed to 65 physician, 22 complete responses were received. Physician responses indicate clinicians would make changes in their choice of Medicare Part B prescription drugs, decrease length of inpatient stay and modify diagnostic tests under the proposed models.   The study supports introducing financial risk to physicians under payment bundling will lead to physician behaviors that lower the cost of care per episode.

Learning Areas:

Administration, management, leadership

Learning Objectives:
Evaluate physician opinions on four proposed models of payment bundling. Compare opinions of employed physicians and physicians who are independent contractors. Discuss aspects of each payment model that are supported or rejected by physicians

Keyword(s): Affordable Care Act, Physicians

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I design the survey and wrote up the results as a project in graduate school. I am a physician, now employed and previously in solo practice and have experience with multiple forms of physician compensation. My interest in payment bundling stems from that experience
Any relevant financial relationships? Yes

Name of Organization Clinical/Research Area Type of relationship
Southern California Permanente Medical Group Physician- general surgery Employment (includes retainer)

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.